Integrated Specific Pathogen Free Research Models and Human New Approach Methodologies to Advance HIV AIDS Research (U42 Clinical Trial Not Allowed)
This grant funds development and integration of human-based research methods and supports high-quality animal models to advance HIV/AIDS research while reducing animal use where possible.
Funder: National Institutes of Health
Due Dates (Anticipated): January 2027 (Full application deadline, projected)
Funding Amounts: Award ceiling: $2,725,311 | Award floor: $212,004 | ~4 awards expected
Summary: Supports integrated development and use of human new approach methodologies (NAMs) and specific pathogen free (SPF) research models to advance HIV/AIDS research.
Key Information: Forecasted opportunity—dates and details may change; check program page for updates.
Description
This opportunity aims to accelerate the development, validation, and adoption of human new approach methodologies (NAMs) in HIV/AIDS research, while maintaining support for high-quality specific pathogen free (SPF) in vivo models where scientifically necessary. The program has two main priorities:
- Implementing a NAMs-enabled stewardship framework to reduce or replace SPF in vivo model use where appropriate, without compromising scientific rigor or translational relevance.
- Supporting robust SPF colony resources for studies that require well-characterized in vivo models.
The NAMs component requires integration of a triage and consultation service to identify NAM-feasible studies and document reductions in animal use, as well as establishing referral pathways to NAM centers and human-based resources. Optional activities include HIV-relevant human in vitro testing support and pilot benchmarking projects for NAMs. The SPF component funds core colony operations, including management, allocation, virologic surveillance, and immunogenetic characterization.
